share_log

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $6

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $6

JMP Securities維持Benitec Biopharma的跑贏大盤,目標股價上調至6美元
Benzinga ·  2023/09/26 09:01

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price target from $4 to $6.

JMP證券分析師Silvan Tuerkcan維持Benitec Biophma(納斯達克:BNTC)的市場表現優於大盤,並將目標價從4美元上調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論